NIH ramps investments in women's health research + VC surge + liquidity + UK NHS FemTech fund + WEF gaps
Key Questions
How much is the NIH directing toward women's health research?
The NIH has directed approximately USD 500 million to women's health research initiatives. This investment aims to address longstanding gaps in funding and clinical trials focused on women-specific conditions.
What was the level of venture capital funding for women's health in 2024?
VC funding reached $2.6 billion in 2024, representing a 55% year-over-year increase. This surge reflects growing investor interest in FemTech and related innovations.
What key gaps and opportunities does the WEF report highlight for women's health?
The WEF notes that only 20% of R&D spending goes to women's health, with less than 3% of trials being women-specific. Closing these gaps could unlock a $1 trillion GDP opportunity by 2040.
What role does the $124 trillion wealth transfer play in women's health investment?
The projected $124 trillion wealth transfer, with a potential 6% allocation, is expected to drive $60 billion in inflows and $100 billion in exits. This capital flow supports M&A activity and de-risking in reproductive and emerging-market health solutions.
Which new regional funds or investments are advancing women's health?
Recent activity includes UNICEF efforts in 11 African and Asian countries, EQ2's $78 million MENA initiative, HealthFab's $2.4 million raise, and the UK NHS £1.5 million FemTech Challenge. Corporate commitments totaling $2.5 billion through 2030 further bolster the sector.
NIH ~USD 500M directed; VC $2.6B 2024 (+55% YoY); WEF: only 20% R&D to women’s health, $1tn GDP opportunity by 2040, <3% women-specific trials; $124T wealth transfer/6% allocation, $60B inflows, $100B exits; UNICEF 11 Africa/Asia; EQ2 $78M MENA; HealthFab $2.4M; UK NHS £1.5M Challenge; $2.5B corporate 2030; Emmeline Ventures signal; new £1→£11 ROI stat. Reinforces M&A/repro de-risking emerging regions.